Cleveland Clinic Lerner Research Institute

09/26/2022

We're moving! To continue seeing our research new and updates, follow us on Twitter, LinkedIn, and Instagram.

06/06/2022

A collaborative research and clinical team at Cleveland Clinic has identified eltrombopag, currently used for the treatment of Aplastic anemia and chronic immune thrombocytopenia, as a potential therapeutic specific for a certain type of leukemia.

Drs. Jha and Maciejewski have identified eltrombopag as a potent inhibitor of specific leukemia cells, which could lead to new drugs that target leukemia cells while preserving and expanding normal blood cells.

06/06/2022

A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment.

Dr. Nima Sharifi and a team of researchers uncovered how tumors circumvent prostate cancer therapy and identified a potential window of time after treatment when tumors may be responsive to immunotherapy.

05/18/2022

A new study led by Lynn Bekris, PhD, Associate Staff in the Genomic Medicine Institute, suggests that inflammatory activity related to the sTREM2 protein may be linked to Alzheimer’s disease (AD) progression.

Dr. Bekris’ team found that patterns of sTREM2-related inflammatory activity were specific to Alzheimer’s disease stages.

05/12/2022

New grant will provide funding to further Dr. Lathia’s research into understanding how the microenvironment generates and maintains immune suppression to fuel the growth of malignant brain tumors.

Dr. Lathia has received an eight-year, $5.2 million award from the National Institute of Neurological Disorders and Stroke to further research into the dynamics of immune suppression in malignant brain tumors and target future immune-activating therapies

05/09/2022

Cleveland Clinic researchers are changing the course of history by establishing the Cleveland Clinic Latino Epidemiology (CCLE) Cohort. The cohort will help close the gap in research participation and health disparities for the Latino population.

With a Cleveland Clinic research co-laboratories award, Drs. Schmit and Mata will establish the Cleveland Clinic Latino Epidemiology (CCLE) Cohort to help close the gap in research participation and health disparities for the Latino population.

05/02/2022

DNA-damaging therapies for colorectal cancer (CRC) can confer resistance to chemotherapy by promoting nuclear translocation of the protein myeloid cell leukemia (MCL1). Evidence suggests that this chemoresistance may be overcome by co-treating the disease with Bcl-xL inhibitors.

Dr. Gastman and collaborators have published findings indicating Bcl-xL inhibitors may help overcome this complication.

04/15/2022

The Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium has received a 3-year, $5.3 million award from the Leona M. and Harry B. Helmsley Charitable Trust to expand its support for the development of a next generation biomarker tool for Crohn’s disease patients with intestinal fibrosis. The award will be split among Cleveland Clinic, Mayo Clinic and Alimentiv, Inc.

The STAR consortium, led by coordinating PI Dr. Rieder, seeks to identify and develop novel biomarkers to help establish effective therapeutics for Crohn’s disease patients with fibrosis.

04/12/2022

A research team led by Jae Jung, PhD, Director of the Global Center for Pathogen & Human Health Research, has uncovered the critical role a viral gene, ORF8, plays in infection and disease outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This is the first published study using samples from the COVID-19 registry of the Cleveland Clinic BioRepository.

Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.

03/16/2022

A Cleveland Clinic research team led by Charis Eng, MD, PhD, has conducted a multicenter cohort study to characterize dermatologic (skin) findings associated with PTEN hamartoma tumor syndrome (PHTS), a spectrum of rare genetic disorders. PHTS impacts multiple organ systems and can result in a wide range of clinical outcomes, such as certain cancers, autism spectrum disorder (ASD) and dermatologic features, including growths and lesions.

Dr. Eng and colleagues conducted a multi-center analysis of skin findings in patients with PTEN hamartoma tumor syndrome.

03/15/2022

In a new study published in npj Genomic Medicine, led by Charis Eng, MD, PhD, has found that distinct metabolite profiles may be associated with either cancer or autism spectrum disorder (ASD) and/or developmental delay (DD) in individuals with PTEN mutations.

Dr. Eng’s team found that distinct metabolite profiles may be associated with either cancer or autism spectrum disorder and/or developmental delay in individuals with PTEN hamartoma tumor syndrome.

03/11/2022

Cleveland Clinic BME researcher Paul Marasco's work engineering a bionic arm that allows wearers to function like a person without an amputation has been honored by the Clinical Research Forum.

Dr. Marasco was honored for engineering a prosthetic that allows the wearer to “think” and function like an able-bodied person.

03/10/2022

According to a recent study published in Neurology, an international team of researchers co-led by the Lerner Research Institute has developed and validated a prediction model to aid in the early diagnosis of Dravet syndrome, a severe epilepsy characterized by drug-resistant seizures, intellectual disability and high mortality that begins in infancy.

Dr. Lal and colleagues have developed a statistical model that integrates genetic and clinical data to calculate the probability of developing Dravet syndrome.

03/04/2022

Cleveland Clinic researchers have received two grants from the National Institute of Neurological Disorders & Stroke to investigate potential causes of multiple sclerosis, an autoimmune disease that affects the central nervous system (brain and spinal cord).

Dr. Dutta is collaborating with other Cleveland Clinic researchers to explore possible novel causes of disease progression in multiple sclerosis, as well as potential therapeutic targets.

03/03/2022

A Cleveland Clinic research team has developed a new model that may aid in the prediction of which melanoma patients will respond to immune checkpoint inhibitor therapy, a type of immunotherapy that stops “checkpoint” proteins from turning off the immune response against cancer cells.

Dr. Gastman’s team found that high levels of a CD8 T-cell subpopulation may predict immune checkpoint inhibitor therapy resistance in melanoma.

02/23/2022

Cleveland Clinic is one of four institutions in the nation to receive a grant from the National Institutes of Health that provides training for early career investigators treating patients with kidney and benign urinary and blood conditions.

Drs. Sedor and Boron are leading a collaboration of Cleveland biomedical institutions to address gaps in community health and training

02/21/2022

Cleveland Clinic has developed a “readmission risk score” instrument that consistently predicts the risk of patient readmission to the hospital.

Dr. Misra-Hebert and colleagues assessed a Cleveland Clinic model’s ability to predict the likelihood that a patient would need to be readmitted to the hospital within 30 days of discharge.

02/17/2022

Cleveland Clinic 2022 Top 10 Medical Innovations list unveils advancements that will transform healthcare/including the next generation of mRNA vaccinology & a new treatment to reduce LDL cholesterol.

Topping the list is the next generation of mRNA vaccinology.